Decentralised clinical trials: ethical opportunities and challenges


Date

2023-06

Publication Type

Journal Article

ETH Bibliography

yes

Citations

Altmetric

Data

Abstract

Fuelled by adaptations to clinical trial implementation during the COVID-19 pandemic, decentralised clinical trials are burgeoning. Decentralised clinical trials involve many digital tools to facilitate research without physical contact between research teams and participants at various stages, such as recruitment, enrolment, informed consent, administering study interventions, obtaining patient-reported outcome measures, and safety monitoring. These tools can provide ways of ensuring participants’ safety and research integrity, while sometimes reducing participant burden and trial cost. Research sponsors and investigators are interested in expanding the use of decentralised clinical trials. The US Food and Drug Administration and other regulators worldwide have issued guidance on how to implement such adaptations. However, there has been little focus on the distinct ethical challenges these trials pose. In this Health Policy report, which is informed by both traditional research ethics and digital ethics frameworks, we group the related ethical issues under three areas requiring increased ethical vigilance: participants’ safety and rights, scientific validity, and ethics oversight. Our aim is to describe these issues, offer practical means of addressing them, and prompt the delineation of ethical standards for decentralised trials.

Publication status

published

Editor

Book title

Volume

5 (6)

Pages / Article No.

Publisher

Elsevier

Event

Edition / version

Methods

Software

Geographic location

Date collected

Date created

Subject

Organisational unit

09614 - Vayena, Eftychia / Vayena, Eftychia check_circle

Notes

Funding

187356 - Digital Health Innovation: a Governance Roadmap for Switzerland (D-GOVmap) (SNF)

Related publications and datasets